Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...

Robert F. Kennedy Jr. cleared his first hurdle on Tuesday to become the nation's top health official when the Senate finance ...

Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...

BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...